cT2N0 papillary cancer with stridor-free airway — extent, prophylactic neck, ablation and calcium consent

Expected management

Choose extent with equivalence, not fear. Bethesda VI carries 3% NIFTP prevalence — small but named — while matched microcarcinoma ties death and recurrence between lobe and total, multifocal disease ties at 3.15/0.78 with complications discounting total, and completion falls post-2015 — so the 3 cm cT2N0 cancer earns total thyroidectomy by size and preference with lobectomy consented as the discussed alternative only where guidelines permit, never by reflex either way.^{[21][22][23][25]}

Justify the central neck node by node. Pooled recurrence runs OR 1.05 ns, RR 0.59 ns (NNT 31), RR 0.66 significant, OR 0.65 with transient nerve and calcium doubled — occult nodes hide in half with permanent calcium 3.45 vs 1.55% — while unrestrained nodal recurrence stays under 10% without survival gain and node-negative dissection halves completion and ablation — so the cN0 neck is dissected only with named justification and calcium consent, not by habit.^{[30][31][32][33][34][35][37]}

Omit or minimise ablation by numbers. Low-dose replaces high-dose (5.9 vs 7.3% at 7 years; pools OR 0.93/0.66) — and IoN omits ablation at 97.9 vs 96.3% for pT1-T2 N0/Nx — so his cT2N0 total thyroidectomy earns 1.1 GBq only where ablation is chosen, with omission where IoN criteria fit.^{[27][28][29][26]}

Consent calcium and voice against volume. Dissection extent leaves palsy tied (3.6/3.9/5.5 transient) while transient calcium climbs 27.7 to 51.9% — and his surgeon's 40 yearly falls below the 50-case inflection with 3%/2.6% reserved above 100 — so the consent quotes the surgeon's denominator with referral offered.^[38][39]

Close with response-based follow-up. Re-stratification at 2 years collapses intermediate risk 21 to 2% with excellent response — thyroglobulin 0.3 marking recurrence risk — so intensity follows response, not presentation.^[48][52]